Sunitinib induced resistance of endothelial cells by up-regulating P-glycoprotein and PI3K/Akt pathway
DOI:
https://doi.org/10.1590/s2175-97902022e191102Keywords:
Drug resistance, Endothelial cells, P-glycoprotein, Sunitinib, PI3K/Akt pathwayAbstract
Drug resistance is a crucial obstacle to achieve satisfactory chemotherapeutic effects. Numerous studies have shown that the PI3K/Akt signaling pathway plays a significant role in various processes of cellular events and tumor progression, while few studies have focused on the PI3K/Akt signaling pathway in drug resistance of endothelial cells. The present study aims to explore the relationship of PI3K/Akt signaling and cellular resistance to anticancer drugs in human microvessel endothelial cells (HMEC-1). We established stable sunitinib-resiatant human microvessel endothelial cells (HMEC-su) after long-term exposure to sunitinib (a small-molecule tyrosine kinase receptor inhibitor) for 12 months. HMEC-su showed significant alternations of cell morphology and exhibited a 2.32-fold higher IC50 of sunitinib than parental HMEC-1 cells. Expression of P-glycoprotein (P-gp) and breast cancer-resistance protein (ABCG2) which mediates drug efflux, increased significantly in HMEC-su lines compared with HMEC-1 cells by western blots assay. Our study further demonstrates that LY294002 (blocking the PI3K/Akt pathway) enhances the sensibility of HMEC-su to suntinib and inhibits the gene transcription and protein expression of P-gp, ABCG2 in HMEC-su cells. In conclusion, these results indicate that LY294002 could reverse P-gp and ABCG2 mediated-drug resistance to sunitinib in HMEC-su cells by inhibiting PI3K/Akt signaling.
Downloads
References
Anreddy N, Gupta P, Kathawala R, Patel A, Wurpel J, Chen Z-S. Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance. Molecules. 2014;19(9):13848-13877.
Breier A, Stetka J, Bohacova V, Macejova D, Brtko J, Sulova Z. Effect of 9-cis retinoic acid and all-trans retinoic acid in combination with verapamil on P-glycoprotein expression in L1210 cells. Neoplasma. 2014;61(5):553-565.
Brayboy LM, Oulhen N, Long S, Voigt N, Raker C, Wessel GM. Multidrug resistance transporter-1 and breast cancer resistance protein protect against ovarian toxicity, and are essential in ovarian physiology. Reprod Toxicol. 2017;69:121-131.
Chen Y, Wang Y, Zhao L, Wang P, Sun J, Bao R, et al. EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation. Cancer Biol Med. 2018;15(1):39-51.
De Gooijer MC, Zhang P, Weijer R, Buil LCM, Beijnen JH, van Tellingen O. The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer. 2018;142(2):381-391.
Elgendy M. The yin yang of Sunitinib: One drug, two doses, and multiple outcomes. Mol Cell Oncol. 2017;4(2):e1285385.
Fan YF, Zhang W, Zeng L, Lei ZN , Cai CY, Gupta P, et al. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. Cancer Lett. 2018;421:186-198.
Guerrouahen BS, Pasquier J, Kaoud NA, Maleki M, Beauchamp MC, Yasmeen A, et al. Akt-Activated Endothelium Constitutes the Niche for Residual Disease and Resistance to Bevacizumab in Ovarian Cancer. Mol Cancer Ther. 2014;13(12):3123-3136.
Hida K, Maishi N, Annan DA, Hida Y. Contribution of Tumor Endothelial Cells in Cancer Progression. Int J Mol Sci. 2018;19(5):1272.
Huang CZ , Wang YF , Zhang Y , Peng YM , Liu YX , Ma F, et al. Cepharanthine hydrochloride reverses Pglycoprotein- mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway. Oncol Rep. 2017;38(4):2558-2564.
Huang L, Perrault C, Coelho-Martins J, Hu C, Dulong C, Varna M, et al. Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy. J Hematol Oncol. 2013;6(49):1-11.
Huang L, Hu C, Di Benedetto M, Varin R, Liu J, Wang L, et al. Induction of multiple drug resistance in HMEC-1 endothelial cells after long-term exposure to Sunitinib. OncoTargets Ther. 2014;7:2249-2255.
Imai Y, Yoshimori M, Fukuda K, Yamagishi H, Ueda Y. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation. Oncol Rep . 2012;27(6):1703-1709.
Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. Lancet. 2016;388(10043):518-529.
Karthikeyan S, Hoti SL. Development of fourth generation abc inhibitors from natural products: A novel approach to overcome cancer multidrug resistance. Anticancer Agents Med Chem. 2015;15(5):605-615.
Kathawala RJ, Gupta P, Ashby CR, Jr., Chen ZS. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat. 2015;18:1-17.
Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, et al. P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. EBio Medicine. 2016;3:54-66.
Li ML, Xu YZ, Lu WJ, Li YH, Tan SS, Lin HJ, et al. Chloroquine potentiates the anticancer effect of Sunitinib on renal cell carcinoma by inhibiting autophagy and inducing apoptosis. Oncol Lett. 2018;15(3):2839-2846.
Li QL, Gu FM, Wang Z, Jiang JH, Yao LQ, Tan CJ, et al. Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma. PLoS ONE. 2012;7(3):e33379.
Liu S, Chen S, Yuan W, Wang H, Chen K, Li D, et al. PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways. Oncotarget. 2017;8(59):99901-99912.
Liu Z, Zhu G, Getzenberg RH, Veltri RW. The Upregulation of PI3K/Akt and MAP kinase pathways is associated with resistance of microtubule-targeting drugs in prostate cancer. J Cell Biochem. 2015;116(7):1341-1349.
Na F, Zhang J, Deng L, Zhou X, Zhou L, Zou B, et al. Continuation of tyrosine kinase inhibitor is associated with survival benefit in nsclc patients with exon 19 deletion after solitary progression. J Cancer. 2017;8(18):3682-3688.
Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets. 2006;7:861-879.
O'Neil BH, Cainap CL, Van Cutsem E, Gorbunova V, S Karapetis C, Berlin J, et al. Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer. Clin Colorectal Cancer. 2014;13(3):156-163 e2.
Peng XX, Tiwari AK, Wu HC, Chen ZS. Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells. Chin J Cancer. 2012;31(2):110-118.
Shah N, Mohammad AS, Saralkar P, Sprowls SA, Vickers SD, John D, et al. Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases. Pharmacol Res. 2018;132:47-68.
Sui H, Pan SF, Feng Y, Jin BH, Liu X, Zhou LH, et al. Zuo Jin Wan reverses P-gp-mediated drug-resistance by inhibiting activation of the PI3K/Akt/NF-kappaB pathway. BMC Complement Altern Med. 2014;14:279.
Wu DP, Liu LG, Yan XB, Wang CY, Wang YL, Han K, et al. Pleiotrophin promotes chemoresistance to doxorubicin in osteosarcoma by upregulating P-glycoprotein. Oncotarget . 2017;8(38):63857-63870.
Wu S, Huang L, Shen R, Bernard‑Cacciarella M, Zhou P, Hu C, et al. Drug resistance-related sunitinib sequestration in autophagolysosomes of endothelial cells. Int J Oncol. 2020;56(1):113-122.
Xie X, Tang B, Zhou JY, Gao Q, Zhang PB. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine. Oncol Rep . 2013;30(2):773-782.
Yazdi MH, Faramarzi MA, Nikfar S, Abdollahi M. Comparative safety and efficacy of tyrosine kinase inhibitors (TKIs) in the treatment setting of different types of leukemia, and different types of adenocarcinoma. Biomed Pharmacother. 2017;95:1556-1564.
Zhang LL, Wang HN, Li W, Zhang JC, Yu RC, Huang HH, et al. Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis. Oncotarget . 2017;8(2):3289-3303.
Zecchin A, Kalucka J, Dubois C, Carmeliet P. How endothelial cells adapt their metabolism to form vessels in tumors. Front Immunol. 2017;8:1750.
Zhou ZG, Wu WL, Liu TT, Peng Y, Lao WQ, Liang M et al. LY294002 blocks the effect of dexamethasone in reducing urine protein in rats by inhibiting PI3K/Akt signaling pathway. Nan Fang Yi Ke Da Xue Xue Bao. 2016;36(12):1727-1731.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
